On July 15, a coalition of the nation’s leading medical and advocacy organizations, led by the American College of Obstetricians and Gynecologists (ACOG), the Society for Women’s Health Research (SWHR), and the Women First Research Coalition (WFRC), formally introduced the National Strategy to Close the Women’s Health Gap. This comprehensive framework represents a historic call to action, urging the United States Congress to authorize and allocate a sustained investment of $20 billion over the next decade. The primary objective of this funding is to fundamentally overhaul the landscape of women’s health research, modernize clinical care delivery, and eliminate the systemic disparities that have historically compromised health outcomes for women across the lifespan.
The strategy emerges at a pivotal moment in American medicine, as healthcare providers and researchers increasingly recognize that the "male-as-default" model of medical study has left significant voids in our understanding of female biology. While the initiative is spearheaded by ACOG, SWHR, and WFRC, it has garnered the endorsement of more than 20 professional medical, patient advocacy, and research organizations, including the Endocrine Society. This broad-based support underscores a growing consensus within the scientific community that the status quo is no longer tenable and that a coordinated, federal response is required to rectify decades of underinvestment.
Historical Context and the Evolution of Women’s Health Policy
To understand the necessity of the National Strategy to Close the Women’s Health Gap, it is essential to examine the legislative history of medical research in the United States. For much of the 20th century, women—particularly those of childbearing age—were often excluded from clinical trials. This exclusion was largely based on concerns regarding fluctuating hormone levels and potential risks to future pregnancies, leading to a medical knowledge base derived primarily from male subjects.
The first major shift occurred in 1993 with the passage of the NIH Revitalization Act. This landmark legislation mandated the inclusion of women and minority groups in clinical research funded by the National Institutes of Health (NIH). While the 1993 Act was transformative, effectively ending the era of "bikini medicine"—where women’s health was viewed almost exclusively through the lens of reproductive organs—it did not fully bridge the gap. Significant disparities remained in how data was analyzed, how findings were implemented in clinical settings, and how much funding was directed toward conditions that disproportionately or differently affect women.
The 2024 National Strategy builds upon the foundation of the 1993 Act but acknowledges that inclusion in trials is only the first step. The current gap is not merely a matter of participation but a systemic failure to account for biological sex as a primary variable in health and disease. The new framework seeks to move beyond mere inclusion toward a comprehensive integration of women’s health into every facet of the national biomedical enterprise.
The Economic and Clinical Imperative for Reform
The call for a $20 billion investment is supported by a growing body of data highlighting the economic and social costs of the women’s health gap. Despite making up more than 50% of the U.S. population, women continue to face longer diagnostic delays for chronic conditions and are more likely to experience adverse drug reactions compared to men.
Supporting data suggests that closing the health gap could provide a significant boost to the global economy. According to a 2024 report by the McKinsey Health Institute and the World Economic Forum, addressing the women’s health gap could potentially add $1 trillion to the global economy annually by 2040. This economic gain stems from increased labor force participation, reduced absenteeism, and a decrease in the burden of caregiving, which disproportionately falls on women.
In the United States, the clinical data is equally compelling. Women are twice as likely as men to be diagnosed with depression and anxiety, and they comprise nearly 80% of all cases of autoimmune diseases, such as lupus, rheumatoid arthritis, and multiple sclerosis. Furthermore, cardiovascular disease remains the leading cause of death for women in the U.S., yet women are frequently underdiagnosed or undertreated because their symptoms often differ from the "classic" male presentation. The National Strategy aims to address these discrepancies by funding research that specifically targets sex-based differences in disease manifestation and treatment response.
Strategic Priorities: A Five-Pillar Framework
The National Strategy to Close the Women’s Health Gap identifies five key priorities designed to create a more equitable healthcare system. While the strategy covers a broad spectrum of medical needs, it focuses on the following core areas:
- Increasing Federal Research Funding: The strategy calls for a massive infusion of capital into the NIH and other federal agencies to support research on conditions that are unique to women, more prevalent in women, or manifest differently in women. This includes menopause, endometriosis, polycystic ovary syndrome (PCOS), and maternal health.
- Modernizing Policy and Regulatory Oversight: Advocates are pushing for updated regulatory frameworks that require sex-disaggregated data in all phases of clinical research and drug development. This ensures that the safety and efficacy of new treatments are validated specifically for female patients before reaching the market.
- Investing in the Specialized Workforce: A critical component of the strategy is the development and support of the women’s health research and clinical workforce. This involves creating incentives for medical students to specialize in women’s health and providing grants for researchers focusing on sex-based biology.
- Improving Access to Evidence-Based Care: The framework emphasizes the need to translate laboratory discoveries into bedside practice more efficiently. This includes updating clinical guidelines and ensuring that insurance providers cover the latest evidence-based treatments for women’s health conditions.
- Data Harmonization and Innovation: By leveraging modern data science and artificial intelligence, the strategy seeks to create integrated databases that allow researchers to track health outcomes for women across different life stages and demographics.
Leadership and Institutional Support
The endorsement of the Endocrine Society brings a crucial perspective to the coalition. Endocrine Society President Nanette Santoro, MD, emphasized the foundational role of hormonal health in women’s overall well-being. "Because hormones influence nearly every aspect of women’s health, advancing research in this area has the potential to improve millions of lives," Dr. Santoro stated. She noted that the strategy’s emphasis on data and clinical care is a vital step toward accelerating progress for women nationwide.
The leadership of the SWHR and ACOG further highlights the multifaceted nature of this initiative. Kathryn Schubert, MPP, CAE, President and CEO of SWHR, noted that the health gap has persisted for too long and that the strategy provides Congress with a clear "roadmap to improve health outcomes, drive innovation, and build a healthier future for women, families, and communities."
ACOG Chief Executive Officer Sandra E. Brooks, MD, MBA, FACOG, pointed out that the human element is just as important as the financial investment. "Closing the women’s health gap requires not only funding research, but also investment in the people who conduct that research and those who translate research findings and discoveries into better patient care," Dr. Brooks said. Her comments reflect a broader concern within the medical community regarding the shortage of specialists and the need for a robust pipeline of researchers dedicated to female-specific health issues.
Broader Impact and Implications for the Future
The introduction of the National Strategy to Close the Women’s Health Gap is expected to trigger a significant legislative debate in Washington. The $20 billion price tag is substantial, but proponents argue that it is a necessary correction for decades of neglect. The strategy aligns with recent executive actions, including the White House Initiative on Women’s Health Research launched in late 2023, suggesting a growing political will to address these issues at the highest levels of government.
The implications of this strategy extend beyond the laboratory and the clinic. By addressing health disparities, the framework also touches upon issues of social justice and health equity. For instance, Black women in the United States are three times more likely to die from pregnancy-related causes than white women. The National Strategy’s focus on maternal health and evidence-based care aims to directly reduce these mortality rates and ensure that high-quality care is accessible to all women, regardless of their socioeconomic or racial background.
Furthermore, the strategy recognizes that women’s health is not a monolithic category. It advocates for research that spans the entire life course—from adolescence and reproductive years through menopause and healthy aging. This "life-course approach" is essential for managing chronic conditions like osteoporosis and Alzheimer’s disease, the latter of which affects women in significantly higher numbers than men.
A Growing Coalition for Change
The breadth of organizations endorsing the strategy is a testament to its perceived urgency. The list includes a diverse array of groups such as the American Heart Association, the Arthritis Foundation, the Black Women’s Health Imperative, and the National MS Society. These organizations represent millions of patients who have a direct stake in the success of this legislative push.
The coalition’s message to Congress is clear: the time for incremental change has passed. The National Strategy to Close the Women’s Health Gap represents a comprehensive, science-driven plan to ensure that the U.S. medical system serves more than half of its population with the same rigor and precision it has historically applied to the other half. As the proposal moves into the legislative arena, its success will depend on the ability of these advocacy groups to demonstrate that an investment in women’s health is not just a matter of fairness, but a prerequisite for a thriving, productive, and healthy nation.
By strengthening the workforce, modernizing policy, and securing a decade of sustained funding, the National Strategy aims to create a legacy of health equity that will benefit generations of women to come. The full strategy is now available for public and legislative review, serving as the definitive blueprint for a new era in American medicine.
